Obesity Week 2025 Medications Obesity Week 2025 Medications Eloralintide, a selective, longacting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept Bhattachar 2026 Diabetes, Obesity and Metabolism Wiley Online Library Cagrilintide Wikipedia Eli Lilly's Eloralintide Phase 2 Trial shows up to 20% Weight Loss with Promising Tolerability in Adults with Obesity Pharmacally Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48 week phase 2, multicentre, double blind, randomised, placebo controlled trial The Lancet